Literature DB >> 14508154

Antimicrobial resistance among gram-positive organisms in the intensive care unit.

Nina M Clark1, Ellie Hershberger, Marcus J Zervosc, Joseph P Lynch.   

Abstract

PURPOSE OF REVIEW: The epidemiology of gram-positive pathogens in the intensive care unit are reviewed, recent trends in antimicrobial resistance among these organisms are discussed, and the significance of these data with respect to treatment are considered. RECENT
FINDINGS: Results of surveillance studies published in 2001 and 2002 have demonstrated that gram-positive organisms such as Staphylococcus aureus, coagulase-negative staphylococci, and enterococci are among the most common bacteria infecting patients in intensive care units. Furthermore, these organisms are becoming increasingly resistant to available antimicrobial agents, and 2002 has ushered in worrisome developments such as the appearance of vancomycin-resistant S. aureus. Community-acquired methicillin-resistant S. aureus and the rise in incidence of vancomycin-resistant enterococci are other problems of great concern. Novel antibiotics such as quinupristin/dalfopristin and linezolid have activity against these agents, but resistance may develop to these agents as well. Studies have shown that infections caused by antibiotic-resistant organisms may be associated with increased morbidity, mortality, and costs. Exposure to antibiotics is a major risk factor for producing antibiotic resistance in patients, and methods to limit the spread of these organisms include restriction of antibiotic use, infection control, surveillance programs, and isolation procedures.
SUMMARY: An awareness of the prevalence and patterns of resistance among gram-positive nosocomial pathogens is vital for the appropriate treatment of hospitalized patients. In addition, efforts must be made to minimize the selection and spread of these organisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508154     DOI: 10.1097/00075198-200310000-00011

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  12 in total

1.  In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.

Authors:  Eun Jeong Yoon; Yeong Woo Jo; Sung Hak Choi; Tae Ho Lee; Jae Keol Rhee; Moohi Yoo; Mi Ja Shim; Eung Chil Choi
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

2.  Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy.

Authors:  A R H van Zanten; M Oudijk; M K E Nohlmans-Paulssen; Y G van der Meer; A R J Girbes; K H Polderman
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

3.  Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  Vanthida Huang; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Heparan sulfate proteoglycans mediate Staphylococcus aureus interactions with intestinal epithelium.

Authors:  Donavon J Hess; Michelle J Henry-Stanley; Stanley L Erlandsen; Carol L Wells
Journal:  Med Microbiol Immunol       Date:  2005-12-24       Impact factor: 3.402

Review 5.  Postoperative spinal wound infections and postprocedural diskitis.

Authors:  Saad B Chaudhary; Michael J Vives; Sushil K Basra; Mitchell F Reiter
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

Review 6.  Recent advances in the chemistry and biology of naturally occurring antibiotics.

Authors:  K C Nicolaou; Jason S Chen; David J Edmonds; Anthony A Estrada
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

7.  In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.

Authors:  Barbara D Foleno; Darren Abbanat; Raul M Goldschmidt; Robert K Flamm; Steve D Paget; Glenda C Webb; Ellyn Wira; Mark J Macielag; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

8.  The N-terminal domain of enterococcal surface protein, Esp, is sufficient for Esp-mediated biofilm enhancement in Enterococcus faecalis.

Authors:  Preeti M Tendolkar; Arto S Baghdayan; Nathan Shankar
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

9.  Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study.

Authors:  Tjasa Hranjec; Laura H Rosenberger; Brian Swenson; Rosemarie Metzger; Tanya R Flohr; Amani D Politano; Lin M Riccio; Kimberley A Popovsky; Robert G Sawyer
Journal:  Lancet Infect Dis       Date:  2012-08-28       Impact factor: 25.071

10.  Suppression of acute lung inflammation by intracellular peptide delivery of a nuclear import inhibitor.

Authors:  Danya Liu; Jozef Zienkiewicz; Antonio DiGiandomenico; Jacek Hawiger
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.